Last reviewed · How we verify
Bio collection
At a glance
| Generic name | Bio collection |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Investigation of the Delve Detect Cerebrospinal Fluid (CSF) Metagenomic Next-generation Sequencing (mNGS) Test When Used for the Initial Diagnostic Workup of Patients With Suspected Central Nervous System (CNS) Infection (NA)
- Bio Clinical Collection of Urothelial Carcinoma
- Identification of New Biomarkers for the Prediction of Cardiovascular Events
- An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors (PHASE1)
- Identification of Genetic Mutations Involved in Chiari Type I Malformations (NA)
- MICI-BIO: Study on Patient With Chronic Inflammatory Bowel Disease (NA)
- A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis
- A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bio collection CI brief — competitive landscape report
- Bio collection updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI